Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab in High vs Low Need Chronic Plaque Psoriasis
NCT00254982Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2005
- Primary completion
- Sep 2006
- Modality
- Monoclonal Antibodies
01
Overview
Phase 3, open-label trial of infliximab in plaque psoriasis (2 arms), sponsored by Merck & Co. Primary endpoint: Proportion of Participants Achieving a Greater Than or Equal to 75% Improvement in Psoriasis Area and Severity Index at 22 weeks. Started Aug 2005; status: completed.
02
Drugs
infliximab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT00254982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00254982.